The small peptide OGP(10-14) acts through Src kinases and RhoA pathways in Mo-7e cells: Morphologic and immunologic evaluation

Department of Human Morphology and Applied Biology, Section of Histology and General Embryology, University of Pisa, Via Roma 67, Pisa, Italy.
Medical science monitor: international medical journal of experimental and clinical research (Impact Factor: 1.43). 07/2008; 14(6):BR103-108.
Source: PubMed


Osteogenic growth peptide (OGP) is an endogenous tetradecapeptide present in micromolar concentrations in mammalian serum; its carboxy-terminal pentapeptide, OGP(10-14), represents its physiologically active fragment. OGP(10-14) induces proliferation and differentiation in fibroblast and osteoblast cell lines, and it enhances hematopoiesis in vitro and in vivo. The signaling pathways triggered by OGP(10-14) are not yet fully known. In the present report, we evaluated the effect of OGP(10-14) on differentiation of a cancer megakaryoblast cell line and its involvement on RhoA and Src family kinases signaling pathway.
Cell proliferation of the Mo-7e line was evaluated using the MTT test. Mo-7e differentiation was evaluated by microscopic observation of cell morphology and by expression of the factor VIII-related antigen. Involvement of RhoA and Src kinases on signaling pathways triggered by OGP(10-14) was analyzed using RhoA and Src family kinase (SFK) inhibitors (C3 and PP2) and an immunoperoxidase technique.
OGP(10-14) induces expression of the factor VIII-related antigen, morphologic changes indicative of megakaryocytic differentiation, and a down-regulation of the Fyn Src kinase. These OGP(10-14) effects were prevented by C3 and enhanced by PP2.
The anti-proliferative and pro-differentiating activities of OGP(10-14) on thrombopoietin (TPO)-primed Mo-7e cells are mediated by RhoA and Src kinase pathways as demonstrated by the use of C3 and PP2.

38 Reads
  • Source
    • "The physiologically active form of OGP, which corresponds to its C-terminal pentapeptide sequence YGFGG (OGP10–14), is generated from full-length OGP by proteolytic cleavage [5]. This fragment directly interacts with cell membrane receptors, activating the MAP kinase, Src and RhoA signaling pathways [9] [10] [11]. Upon intravenous administration, synthetic OGP and OGP10–14 were shown to promote increased bone mass and fracture healing in vivo [12] [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The outcome of cell-based therapies can benefit from carefully designed cell carriers. A multifunctional injectable vehicle for the co-delivery of human mesenchymal stem cells (hMSC) and osteoinductive peptides is proposed, to specifically direct hMSC osteogenic differentiation. The osteogenic growth peptide (OGP) inspired the design of two peptides, where the bioactive portion of OGP was flanked by a protease-sensitive linker, or its scrambled sequence, to provide faster and slower release rates, respectively. Peptides were fully characterized and chemically grafted to alginate. Both OGP analogues released bioactive fragments in vitro, at different kinetics, which stimulated hMSC proliferation and osteogenesis. hMSC-laden OGP-alginate hydrogels were tested at an ectopic site in a xenograft mouse model. After 4weeks, OGP-alginate hydrogels were more degraded and colonized by vascularized connective tissue than the control (without OGP). hMSC were able to proliferate, migrate outward the hydrogels, produce endogenous extracellular matrix and mineralize it. Moreover, OGP-groups stimulated hMSC osteogenesis, as compared with the control. Overall, the ability of the proposed platform to direct the fate of transplanted hMSC in loco was demonstrated, and OGP-releasing hydrogels emerged as a potentially useful system to promote bone regeneration.
    Full-text · Article · Jun 2014 · Journal of Controlled Release
  • Source
    • "PP2 SFK inhibitor was dissolved in DMSO and added to cell cultures 40 minutes before adding OGP(10-14). DMSO was used at a concentration that does not interfere with M07-e cell proliferation [9]. Experiments were performed at 1, 72 and 144 hours on the basis of the previous results, showing in M07-e cells RhoA activation and signs of differentiation at 1h and 144h, respectively [9]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteogenic growth peptide (OGP) is a 14-mer peptide found in relevant concentration in blood, and its carboxy-terminal fragment [OGP(10-14)] represents the active portion of the full-length peptide. In addition to stimulating bone formation, OGP(10-14) shows hematological activity. In fact, it highly enhances hematopoiesis-affecting stem progenitors. Moreover, OGP(10-14) reduces the growth and induces the differentiation of the hematological tumour cell line trombophoietin(TPO)-primed M07-e by interfering with RhoA and Src kinase pathways. In the present report, we went deeper into this mechanism and evaluated the possible interference of the OGP(10-14) signal pathway with TGFβ1 and TPO receptor Mpl. In OGP(10-14)-treated M07-e cells cultured with or without RhoA and Src kinases inhibitors (C3 and PP2), expression of TGFβ1, Mpl, and Src kinases was analyzed by immunoperoxidase technique. Activated RhoA expression was studied using the G-LISA™ quantitative test. In M07-e cells, both OGP(10-14) and PP2 activate RhoA, inhibit Src kinases, reduce Mpl expression and increase TGFβ1 expression. OGP(10-14) and PP2 show the same behavior, causing an additive effect when associated. OGP(10-14) induces TPO-primed M07-e cells differentiation through RhoA/TGFβ1/SFKs signalling pathway. In particular OGP(10-14) acts as a Src inhibitor, showing the same effects of PP2.
    Full-text · Article · Jan 2011 · Medical science monitor: international medical journal of experimental and clinical research
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we report the use of surface immobilized peptide concentration gradient technology to characterize MC3T3-E1 osteoblast cell response to osteogenic growth peptide (OGP), a small peptide found naturally in human serum at mumol/L concentrations. OGP was coupled to oxidized self assembled monolayer (SAM) gradients by a polyethylene oxide (PEO) linker using click chemistry. After 4h incubation with MC3T3-E1 cells, OGP functionalized surfaces had higher cell attachment at low peptide concentrations compared to control gradients. By day 3, OGP gradient substrates had higher cell densities compared to control gradients at all concentrations. MC3T3-E1 cell doubling time was 35% faster on OGP substrates relative to SAM gradients alone, signifying an appreciable increase in cell proliferation. This increase in cell proliferation, or decrease in doubling time, due to OGP peptide was reduced by day 7. Hence, immobilized OGP increased cell proliferation from 0 days to 3 days at all densities indicating it may be useful as a proliferative peptide that can be used in tissue engineering substrates.
    No preview · Article · Nov 2009 · Biomaterials
Show more